[Skip to Navigation]
Comment & Response
October 29, 2020

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply

Author Affiliations
  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York
JAMA Oncol. 2020;6(12):1983. doi:10.1001/jamaoncol.2020.4824

In Reply We thank Qi and colleagues for their careful review of our article and their thoughtful comments. We agree that the progression-free survival (PFS) of the osimertinib and bevacizumab combination seen in our study1 is comparable to the median PFS with osimertinib alone in the FLAURA study.2 In our article, we note that there was a larger proportion of patients with preexisting brain metastases compared with the FLAURA population (31% vs 19%), and 16% of patients withdrew consent without progression and unrelated to toxic effects to pursue consolidative local therapy (n = 4) or continue with commercial osimertinib (n = 4). These factors may have influenced the PFS in our study.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words